Samsung Biologics held a Supplier Environmental, Social and Governance (ESG) Day on Tuesday to encourage suppliers to strengthen their ESG management.
The event took place at Samsung Biologics' headquarters in Songdo International City, Incheon, and was attended by 26 major global suppliers, including Merck, Cytiva, Thermo Fisher, and Sartorius. A total of 100 executives and ESG representatives from each company participated.
Throughout the day, Samsung Biologics conducted various programs aimed at deepening participants' understanding of ESG. These included discussions on ESG regulatory trends, sustainability management strategies, recognition of suppliers with outstanding ESG activities, and the sharing of relevant case studies.
Participants were also introduced to the Sustainable Markets Initiative (SMI), which Samsung Biologics chairs in the health system task force.
The SMI was launched in 2020 by King Charles III of the U.K. to address global climate change.
The event concluded with the presentation of the Best ESG Supplier Awards and case sharing.
This year's winners were Thermo Fisher and Merck. The companies were recognized for their excellent performance in waste management, climate change commitments, and active collaboration on ESG data.
Thermo Fisher and Merck shared their best practices in ESG activities, especially their carbon reduction activities and sustainability management strategies in collaboration with Samsung Biologics.
"As the chair of the SMI's health system task force, we are actively working with our global customers and suppliers to respond to the global challenge of climate change," said John Rim, CEO of Samsung Biologics. "We will continue to expand our partnerships with suppliers to reduce carbon emissions with a sense of mission to improve human health."
Related articles
- Samsung Biologics tops ₩3 trillion in annual orders for 1st time ever
- Samsung Biologics posts record-high quarterly sales in Q3 thanks to Plant 4
- Samsung Biologics, Kurma Partners team up to support biotech startups
- Samsung Biologics expects 20% surge in annual sales, riding high on Plant 4 success
- Samsung Biologics gets EcoVadis' highest ESG rating
- Samsung Biologics posts over ₩1 trillion annual operating profit in 2023, 1st in Korean pharma